Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Immunological Tolerance and Regulation
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1447897
This article is part of the Research Topic Immunological tolerance and regulation in Allergen-Specific Immunotherapy (AIT) View all 13 articles

Dendritic cells transfected with DNA constructs encoding CCR9, IL-10, and type II collagen demonstrate induction of immunological tolerance in an arthritis model

Provisionally accepted
Sergey V. Sennikov Sergey V. Sennikov 1*Marina Fisher Marina Fisher 1*Vasily Kurilin Vasily Kurilin 1*Aleksey Bulygin Aleksey Bulygin 1Julia Philippova Julia Philippova 1Julia Shevchenko Julia Shevchenko 1*Elena Ivleva Elena Ivleva 2*Oleg Taranov Oleg Taranov 2Amir Maksyutov Amir Maksyutov 1,2
  • 1 Research Institute of Fundamental and Clinical Immunology (RIFCI), Novosibirsk, Russia
  • 2 State Research Center of Virology and Biotechnology VECTOR (ISTC), Kol'tsovo, Novosibirsk Oblast, Russia

The final, formatted version of the article will be published soon.

    Introduction: Restoring immune tolerance is a promising area of therapy for autoimmune diseases.One method that helps restore immunological tolerance is the approach using tolerogenic dendritic cells (tolDCs). In our study, we analyzed the effectiveness of using dendritic cells transfected with DNA constructs encoding IL-10, type II collagen, and CCR9 to induce immune tolerance in an experimental model of arthritis. Methods: Dendritic cell cultures were obtained from bone marrow cells of Balb/c mice. Dendritic cells (DCs) cultures were transfected with pmaxCCR9, pmaxIL-10, and pmaxCollagen type II by electroporation. The phenotype and functions of DCs were studied using enzyme-linked immunosorbent assay (ELISA) and flow cytometry. Migration of electroporated DCs was assessed in vitro. Induction of antigen-collagen induced arthritis (ACIA) was carried out according to the protocol in Balb/c mice. DCs were then administered to ACIA mice. The development of arthritis was monitored by measuring paw swelling with a caliper at different time points. The immunological changes were assessed by analyzing the content of antibodies to type II collagen using enzyme immunoassay. Additionally, a histological examination of the joint tissue was conducted, followed by data analysis. The results are as follows: DCs were obtained, characterized by reduced expression of CD80, CD86, and H-2Db (MHC class I), increased expression of CCR9, as well as producing IL-10 and having migratory activity to thymus cells. Transfected DCs induced T-regulatory cells (T-reg) and Отформатировано: Шрифт: курсив increased the intracellular content of IL-10 and TGF-β in CD4 + T cells in their co-culture, and also suppressed their proliferative activity in response to antigen. The administration of tolDCs transfected with DNA constructs encoding type II collagen, IL-10, and CCR9 to mice with ACIA demonstrated a reduction in paw swelling, a reduction in the level of antibodies to type II collagen, and a regression of histological changes. Conclusion: The study presents an approach by which DCs transfected with DNA constructs encoding epitopes of type II collagen, IL-10 and CCR9 promote the development of antigenspecific tolerance, control inflammation and reduce the severity of experimental arthritis through the studied mechanisms: induction of T-reg, IL-10, TGF-β.

    Keywords: immunological tolerance, tolerant dendritic cells, experimental arthritis, antigen-specific dendritic cells, DNA-constructs, T-regulatory cells

    Received: 12 Jun 2024; Accepted: 18 Jul 2024.

    Copyright: © 2024 Sennikov, Fisher, Kurilin, Bulygin, Philippova, Shevchenko, Ivleva, Taranov and Maksyutov. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Sergey V. Sennikov, Research Institute of Fundamental and Clinical Immunology (RIFCI), Novosibirsk, Russia
    Marina Fisher, Research Institute of Fundamental and Clinical Immunology (RIFCI), Novosibirsk, Russia
    Vasily Kurilin, Research Institute of Fundamental and Clinical Immunology (RIFCI), Novosibirsk, Russia
    Julia Shevchenko, Research Institute of Fundamental and Clinical Immunology (RIFCI), Novosibirsk, Russia
    Elena Ivleva, State Research Center of Virology and Biotechnology VECTOR (ISTC), Kol'tsovo, 630559, Novosibirsk Oblast, Russia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.